Rui Liang Email & Phone Number

New York, New York, US

Rahway, New Jersey, US

• Collaborated with computational chemists to use structure based drug design, ligand docking, FEP, MPO, virtual screening studies for target proposal and chemoinformatics softwares for in silico prediction of compound.
• Supported the delivery of a clinical candidate for a cancer program. Designed and synthesized novel and potent key compounds with multiple points of modification enabling strong IP protection in patent filing.
• Successfully delivered tool compounds with over 500 folds increase in potency and full agonism starting from a HTS hit for natriuretic peptide receptor agonist (NPRA) program in hypertension. Solution of these ligand.
• Evaluated the efficacy of TGR5 receptor (or GP-BAR1, or M-BAR) agonist with "gut-only" approach. Led chemistry efforts in design and synthesis of novel dendrimer bound TGR5 receptor agonists. Collaborated across.
• Delivered tool compounds as integrin inhibitors for assay development, PK profiling and PD efficacy studies in kidney/liver/lung fibrosis.

Rahway, New Jersey, US

• Lead Identification and Target Validation:
• Investigated small molecule inhibitors for protein-protein interactions in PCSK9 program for atherosclerosis. Identified a critical interaction to enhance binding with PCSK9 protein with non-acid residue. Explored.
• Chemistry Champion for PCSK8 program. Managed project transfer from Japan back to Rahway, NJ. Delivered 5 PCSK8 peptide substrates, 2 luciferin labeled peptides and 3 FRET labeled peptides for assay development and the.
• Delivered potent and selective inhibitors for DGAT2 program.Lead optimization: key contributor to Niacin, sEH, sGC and GKA backup programs. Solved challenging synthetic problems and enabled the preparation of selective.
• Supported the delivery of 3 clinical candidates MK-0354, MK-0727 and MK-1903 for the Niacin receptor agonist program for atherosclerosis. Both MK-0354 and MK-1903 advanced to Phase II in clinical trials.
• Developed potent, bioavailable and selective aminopyridine sEH inhibitor guided with crystal structure and molecular modeling.

Rahway, New Jersey, US

• Member of glucagon receptor antagonist (GRA) medicinal chemistry team targeting treatment for type II diabetes.
• Designed and synthesized conformational constrained tri-substituted urea antagonists that showed potent activity and excellent PK properties. One such compound was efficacious in normalizing glucose level in both acute.
• Discovered a chiral substituent critical to improve potency and PK properties in tri-substituted pyrazole antagonists. This chiral substituent was successfully incorporated into clinical candidates MK-0893 and MK-3577.

• Led chemistry efforts on the discovery of novel macrolides.
• Business development: assisted project transfer and company transition to site closure. Note: Theravance, Inc., previously known as Advanced Medicine, Inc., now Innoviva

• Chemistry Lead on the macrolide program for infectious disease with the goal of overcoming the MLS (Macrolides-Lincosamides-Streptogramins) resistance induced by efflux-pump mechanism and/or methylase activity.
• Implemented a macrolide program focused on carbohydrate modification. Established chemistry to modify carbohydrates on 14- and16-membered macrolides using combinatorial chemistry approach.
• Involved in scientific presentation for company acquisition by Advance Medicine, Inc. Note: Transcell Technologies, Inc. was acquired by Intercardia Research Laboratory in 1998, later became Incara Research Laboratory.

• Discovery of novel disaccharide anti-bacterial agents targeting bacterial cell wall synthesis and protein synthesis.
• Developed solid phase chemistry to synthesize fully deprotected moenomycin analogs on photocleavable resin (11 steps on solid support).
• Established a synthetic route for the construction of combinatorial libraries of 1300 moenomycin analogs on photocleavable resin using IRORI AccuTag system.
• Developed solution chemistry for the scale-up synthesis of hit ligands from the moenomycin libraries.Note: Transcell Technologies, Inc. was acquired by Intercardia Research Laboratory in 1998Sofia, M. J.; Allanson, N..

Ph.D., Organic Chemistry

Organic Chemistry

Bs, Chemistry